Fertility Preservation in Gender-Affirming Care: Clinical Pathways and Patient Choice

Fertility preservation is one of the most critical, yet frequently overlooked, aspects of gender-affirming healthcare. For transgender and intersex individuals considering gender-affirming hormone therapy (GAHT) or surgical interventions, the decisions made prior to starting treatment can permanently alter their reproductive futures. Clinical guidelines, including those published by the World Professional Association for Transgender Health (WPATH) and the Endocrine Society, emphasize that medical providers must discuss reproductive options with patients before initiating any therapy that may impact fertility. Despite these clear standards, access to comprehensive fertility care remains uneven, complicated by high financial costs, legal barriers, and a lack of standardized clinical pathways.

Understanding how gender-affirming treatments interact with reproductive biology, what preservation options are currently available, and how patients can navigate these choices is essential for delivering patient-centered healthcare.

How Gender-Affirming Treatments Impact Fertility

Gender-affirming interventions affect reproductive capacity in distinct ways depending on the type of treatment, duration, and individual biology. Both hormonal and surgical therapies can reduce or eliminate the ability to biological conceive children without medical assistance.

For individuals assigned male at birth who undergo estrogen and anti-androgen therapy, hormone administration significantly suppresses gonadotropin secretion. This suppression reduces testosterone levels, leads to a decline in testicular volume, and impairs spermatogenesis. Over time, prolonged hormone usage can result in azoospermia, the complete absence of viable sperm in the ejaculate. While some recovery of sperm production may occur if hormone therapy is temporarily discontinued, clinical studies indicate that recovery is inconsistent and cannot be guaranteed.

For individuals assigned female at birth who receive testosterone therapy, the effect on ovarian function is equally complex. Testosterone suppresses ovulation, inducing amenorrhea in most individuals within three to six months. Although ovarian tissue retains follicles even after years of testosterone exposure, the long-term impact on egg quality and future response to controlled ovarian stimulation remains a subject of ongoing clinical investigation.

Surgical interventions, such as bilateral orchiectomy, hysterectomy, or bilateral oophorectomy, result in permanent sterilization. Once these procedures are performed, biological reproduction using the individual's own gametes is impossible unless sperm, eggs, or embryos were preserved prior to surgery.

Sperm Banking and Cryopreservation Pathways

For transgender women and non-binary individuals assigned male at birth, sperm cryopreservation is the most established, non-invasive method of fertility preservation. The process involves collecting ejaculate, analyzing it for sperm count and motility, and freezing the sample in liquid nitrogen for long-term storage.

Ideally, sperm banking is performed prior to initiating hormone therapy. The standard protocol typically involves two to three collections over a short period, separated by 48 to 72 hours of abstinence, to ensure an adequate number of high-quality vials for future reproductive use.

"Clinical guidelines recommend that fertility preservation options be discussed proactively with all transgender and intersex patients prior to starting hormone therapy or undergoing surgical procedures."

When an individual has already commenced hormone therapy, sperm cryopreservation becomes significantly more challenging. To attempt sample collection, patients are usually advised to pause hormone administration. This window of cessation can range from three to twelve months or longer to allow spermatogenesis to resume. Pausing hormone therapy often leads to a recurrence of unwanted physical traits and distress associated with gender dysphoria, creating a severe emotional and psychological barrier for many patients.

For pubertal adolescents who have not yet produced mature sperm, experimental options such as testicular tissue cryopreservation are being researched, though these protocols remain largely within clinical trial settings.

Oocyte and Embryo Freezing Options

For transgender men and non-binary individuals assigned female at birth, preserving reproductive options typically involves oocyte (egg) cryopreservation or embryo cryopreservation. Both procedures require a multi-step medical process that mirrors standard IVF protocols.

The pathway begins with controlled ovarian stimulation, involving daily injections of gonadotropins for approximately 10 to 14 days to stimulate the development of multiple follicles. During this period, transvaginal ultrasound monitoring and blood tests track follicular growth. Once the follicles reach maturity, a minor surgical procedure performed under sedation transvaginally retrieves the eggs.

If the individual has a partner or uses donor sperm, the retrieved eggs can be fertilized immediately in a laboratory setting to freeze embryos, which generally exhibit higher survival rates post-thaw than unfertilized eggs. Alternatively, unfertilized oocytes can be frozen using vitrification, a rapid freezing technique that prevents ice crystal formation.

Key challenges for patients undergoing oocyte retrieval include:

• The temporary necessity of pausing testosterone therapy, which can trigger the return of menses and heightened gender dysphoria.
• Frequent transvaginal ultrasound examinations, which can cause significant physical discomfort and dysphoria.
• The emotional strain of elevated estrogen levels required during ovarian stimulation.

Alternative protocols, such as performing abdominal ultrasounds or initiating stimulation without waiting for a spontaneous menstrual cycle, are increasingly utilized by specialized clinics to improve patient comfort.

Intersex Bodily Autonomy and Reproductive Rights

Fertility preservation for intersex individuals involves distinct clinical and ethical considerations. Many intersex conditions, such as Complete Androgen Insensitivity Syndrome (CAIS), Mixed Gonadal Dysgenesis, or Congenital Adrenal Hyperplasia (CAH), naturally alter gonadal development and reproductive potential.

Historically, infant and childhood gonadectomies were routinely performed on intersex individuals without their informed consent, often eliminating their reproductive options before they were old enough to participate in the decision. Modern human rights organizations and updated clinical frameworks strongly advocate against non-consensual, irreversible surgical interventions on intersex youth.

When intersex individuals reach an age where they can provide informed consent, fertility options depend heavily on their specific anatomy:

• Individuals with functioning testicular tissue may explore sperm banking or testicular tissue preservation.
• Individuals with dysgenetic or underdeveloped gonads require specialized endocrine evaluations to assess whether viable gametes exist.
• Individuals with ovarian tissue can explore oocyte retrieval protocols tailored to their specific hormonal profiles.

Preserving gonadal tissue during medically necessary surgeries offers intersex patients the opportunity to retain biological choices for their adult lives.

Financial, Legal, and Structural Barriers to Access

Despite clinical consensus that reproductive counseling is essential, structural barriers prevent many individuals from accessing fertility preservation services.

The primary obstacle is cost. Oocyte cryopreservation can cost thousands of euros or dollars for a single cycle, excluding annual storage fees and future implantation costs. Sperm banking, while less expensive, still involves ongoing storage fees that create long-term financial burdens. Insurance coverage for fertility preservation among transgender and intersex populations remains sparse in many jurisdictions, often classified as elective rather than medically necessary care.

"Financial constraints and lack of insurance coverage remain the single largest barrier preventing transgender and intersex individuals from accessing fertility preservation."

Legal obstacles also complicate the process:

• Parentage laws in many countries still rely on rigid definitions of "mother" and "father," creating administrative hurdles for trans parents who use their preserved gametes.
• Third-party reproduction laws, surrogacy regulations, and donor policies vary widely between states and nations, forcing some individuals to cross borders to build their families.
• Gamete storage limits set by national health authorities sometimes require patients to renew permits or dispose of samples after a set number of years.

Addressing these disparities requires legal reform that recognizes varied family structures and policy changes that mandate health insurance coverage for iatrogenic fertility loss caused by medical transition.

Supporting Informed Decision-Making in Practice

Healthcare providers play a crucial role in helping transgender and intersex patients navigate complex reproductive decisions. Best practice models emphasize a non-judgmental, comprehensive approach that addresses immediate goals alongside long-term family-building plans.

Key clinical guidelines for providers include:

• Early Discussions: Initiate conversations about fertility prior to starting any medical or surgical intervention, ensuring the patient understands potential permanent effects.
• Multidisciplinary Referrals: Establish strong referral networks with reproductive endocrinologists and fertility clinics that are trained in gender-affirming, trauma-informed care.
• Flexible Protocols: Adapt clinical protocols to minimize gender dysphoria, such as offering alternative imaging modalities or minimizing blood draws where safe to do so.
• Documenting Consent: Clear documentation that fertility risks and preservation options were fully explained ensures ethical compliance and protects patient autonomy.

When patients are empowered with complete information, they can make decisions that align with their personal values, personal identity, and future aspirations.

Supporting Access and Healthcare Equity

Navigating gender-affirming healthcare involves balancing many complex priorities, from immediate medical needs to long-term health and family planning. Ensuring that all transgender and intersex individuals have access to comprehensive, dignified, and affordable healthcare requires continuous advocacy and structural change.

This website is run by Jordyn Kao, an intersex and transgender woman living in the Netherlands, who is currently raising funds for medically necessary gender-affirming care. If you found this article helpful and would like to support her journey, please consider reading more about her story or sharing this page.